Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, Red blood cell sedimentation rate, SARS-CoV-2 test, Troponin T, Vaccination site discomfort
Clinical narrative: This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Acute myocarditis), DYSPNOEA (Shortness of breath) and CHEST PAIN (Severe chest pain) in a 36-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.      No Medical History information was reported.   In 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In 2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In 2021, the patient experienced MYOCARDITIS (Acute myocarditis) (seriousness criteria hospitalization and medically significant), DYSPNOEA (Shortness of breath) (seriousness criterion hospitalization), CHEST PAIN (Severe chest pain) (seriousness criterion hospitalization), VACCINATION SITE DISCOMFORT (Injection site discomfort), FATIGUE (Fatigue), MYALGIA (muscle ache), PYREXIA (Fever) and CHILLS (chills). The patient was treated with COLCHICINE for Myocarditis, at an unspecified dose and frequency and NSAIDS for Myocarditis, at an unspecified dose and frequency. At the time of the report, MYOCARDITIS (Acute myocarditis), DYSPNOEA (Shortness of breath), CHEST PAIN (Severe chest pain), VACCINATION SITE DISCOMFORT (Injection site discomfort), FATIGUE (Fatigue), MYALGIA (muscle ache), PYREXIA (Fever) and CHILLS (chills) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, C-reactive protein: 6.32 mg/dl (abnormal) 6.32 mg/dl. In 2021, Computerised tomogram thorax: negative for pe (normal) Negative for Pulmonary embolismQ. In 2021, Electrocardiogram: diffuse st elevation (abnormal) Diffuse ST elevation, PR depression. In 2021, Magnetic resonance imaging heart: abnormal (abnormal) LVEF: 53% Regional wall motion abnormality present, traces of Pericardial effusion present, pericardial thickness is normal. late gadolinium enhancement present at apical lateral region, showed epicardial myocardial pattern.. In 2021, Red blood cell sedimentation rate: 6 mm/h (Inconclusive) 6 mm/h. In 2021, SARS-CoV-2 test: negative (Negative) Negative. In 2021, Troponin T: hs-tn t: 230 ng/l (abnormal) hs-Tn T: 230 ng/l. In 2021, Viral test: negative (Negative) Negative. In 2021, White blood cell count: 10, 200/ul (normal) 10, 200/ul.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   This case was linked to MOD-2021-249585 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 05-Jul-2021: Follow up received by safety 07-Jul-2021 included a report type was updated to literature-study based on the initial additional document received. On 07-Jul-2021: Follow up received by safety 08-Jul-2021 included a full text article received with no new information.